Avidity holds exclusive rights to the patented biotin-accepting peptides (AviTag) technology. Currently, this technology is licensed by 7 out of the top 10 leading pharmaceutical companies and is used by researchers in 22 countries. AviTag technology exploits the tight interaction of avidin or streptavidin with biotin for immobilizing, purifying and visualizing proteins. Immobilized AviTag-fusion proteins are used for applications ranging from high-throughput screening (HTS) to protein-protein interactions using surface plasmon resonance. Purification of AviTag-fusion proteins using monomeric avidin can be more efficient than the commonly used hexa-HIS or Strep-tag® technologies (Tucker and Grishammer) and AviTag-fusion proteins can be visualized using avidin or streptavidin conjugates such as Western Blots and MHC tetramers for staining and sorting T cells.
